10x Genomics (NYSE: TXG) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.
10x Genomics, Inc. (TXG)
Last 10x genomics, inc. earnings: 2/18 04:01 pm
Check Earnings Report
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
TXG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TXG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TXG alerts
High impacting 10x Genomics, Inc. news events
Weekly update
A roundup of the hottest topics
TXG
News
- 2 Reasons to Sell TXG and 1 Stock to Buy Instead [Yahoo! Finance]Yahoo! Finance
- 10x Genomics, Inc. (NASDAQ: TXG) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.MarketBeat
- PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program [Yahoo! Finance]Yahoo! Finance
- 10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Citigroup Inc. from $20.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Parse Biosciences Advances Plans to Release Single Cell Chromatin Accessibility Products [Yahoo! Finance]Yahoo! Finance
TXG
Earnings
- 2/12/25 - Miss
TXG
Sec Filings
- 3/4/25 - Form 4
- 2/28/25 - Form 144
- 2/26/25 - Form 4
- TXG's page on the SEC website